Literature DB >> 19018457

Improved methods for testing antiresorptive compounds in human osteoclast cultures.

Jukka P Rissanen1, Hannele Ylipahkala, Katja M Fagerlund, Clive Long, H Kalervo Väänänen, Jussi M Halleen.   

Abstract

We cultured human bone marrow-derived stem cells on bovine bone slices in 96-well plates in the presence of M-CSF and RANKL, allowing them to differentiate into osteoclasts. Secreted TRACP 5b was a useful endpoint measurement to demonstrate effects of inhibitors of osteoclast differentiation in the culture system, reflecting accurately the number of formed osteoclasts. Inhibitors of osteoclast activity were added into the cultures after the differentiation period, and the cultures were continued to allow the formed osteoclasts to resorb bone. CTX values obtained after the resorption period were normalized with TRACP 5b values obtained after the differentiation period, before adding the inhibitors. This normalization prevents false results that could be obtained from the presence of different amounts of osteoclasts in different wells before adding the inhibitors. These results demonstrate that the use of TRACP 5b and CTX allows rapid and reliable testing of antiresorptive compounds in human osteoclast cultures.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018457     DOI: 10.1007/s00774-008-0002-1

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  16 in total

1.  Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.

Authors:  S Christgau; C Rosenquist; P Alexandersen; N H Bjarnason; P Ravn; C Fledelius; C Herling; P Qvist; C Christiansen
Journal:  Clin Chem       Date:  1998-11       Impact factor: 8.327

2.  Generation of multinuclear tartrate-resistant acid phosphatase positive osteoclasts in liquid culture of purified human peripheral blood CD34+ progenitors.

Authors:  L Pierelli; G Scambia; G d'Onofrio; M Ciarli; A Fattorossi; G Bonanno; G Menichella; A Battaglia; P Benedetti Panici; M Tommasi; S Mancuso; G Leone
Journal:  Br J Haematol       Date:  1997-01       Impact factor: 6.998

3.  Resorption of dentine by isolated osteoclasts in vitro.

Authors:  A Boyde; N N Ali; S J Jones
Journal:  Br Dent J       Date:  1984-03-24       Impact factor: 1.626

4.  Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood.

Authors:  Mette Grøndahl Sørensen; Kim Henriksen; Sophie Schaller; Dennis Bang Henriksen; Finn Cilius Nielsen; Morten Hanefeld Dziegiel; Morten Asser Karsdal
Journal:  J Bone Miner Metab       Date:  2007-01-01       Impact factor: 2.626

5.  Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium.

Authors:  S L Alatalo; J M Halleen; T A Hentunen; J Mönkkönen; H K Väänänen
Journal:  Clin Chem       Date:  2000-11       Impact factor: 8.327

6.  Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis.

Authors:  Pauling Chu; Tsu-Yi Chao; Yuh-Feng Lin; Anthony J Janckila; Lung T Yam
Journal:  Am J Kidney Dis       Date:  2003-05       Impact factor: 8.860

7.  Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.

Authors:  Rosemary A Hannon; Jackie A Clowes; Alison C Eagleton; Amna Al Hadari; Richard Eastell; Aubrey Blumsohn
Journal:  Bone       Date:  2004-01       Impact factor: 4.398

8.  A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum.

Authors:  Sari L Alatalo; Zhiqi Peng; Anthony J Janckila; Helena Kaija; Pirkko Vihko; H Kalervo Vaananen; Jussi M Halleen
Journal:  J Bone Miner Res       Date:  2003-01       Impact factor: 6.741

9.  The effects of bisphosphonates on the resorption cycle of isolated osteoclasts.

Authors:  K Selander; P Lehenkari; H K Väänänen
Journal:  Calcif Tissue Int       Date:  1994-11       Impact factor: 4.333

10.  A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro.

Authors:  J M Quinn; J Elliott; M T Gillespie; T J Martin
Journal:  Endocrinology       Date:  1998-10       Impact factor: 4.736

View more
  5 in total

1.  Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

Authors:  Jinlu Dai; Honglai Zhang; Andreas Karatsinides; Jill M Keller; Kenneth M Kozloff; Dana T Aftab; Frauke Schimmoller; Evan T Keller
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

2.  Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality.

Authors:  Anita V Neutzsky-Wulff; Mette G Sørensen; Dino Kocijancic; Diana J Leeming; Morten H Dziegiel; Morten A Karsdal; Kim Henriksen
Journal:  BMC Musculoskelet Disord       Date:  2010-06-01       Impact factor: 2.362

3.  Short-term jump activity on bone metabolism in female college-aged nonathletes.

Authors:  Kohei Kishimoto; Ryan P Lynch; Jamie Reiger; Vanessa R Yingling
Journal:  J Sports Sci Med       Date:  2012-03-01       Impact factor: 2.988

4.  A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells.

Authors:  Hélène Haegel; Christine Thioudellet; Rémy Hallet; Michel Geist; Thierry Menguy; Fabrice Le Pogam; Jean-Baptiste Marchand; Myew-Ling Toh; Vanessa Duong; Alexandre Calcei; Nathalie Settelen; Xavier Preville; Marie Hennequi; Benoit Grellier; Philippe Ancian; Jukka Rissanen; Pascal Clayette; Christine Guillen; Ronald Rooke; Jean-Yves Bonnefoy
Journal:  MAbs       Date:  2013-07-15       Impact factor: 5.857

5.  Osteoclastic differentiation and resorption is modulated by bioactive metal ions Co2+, Cu2+ and Cr3+ incorporated into calcium phosphate bone cements.

Authors:  Anne Bernhardt; Martha Schamel; Uwe Gbureck; Michael Gelinsky
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.